Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...

Approved for the same indications as the reference product, STEQEYMA will be priced with a wholesale acquisition cost (WAC) list price at an 85% discount to the current WAC list price of STELARA ...

Mounjaro and Trulicity are two injectable medications that treat type 2 diabetes. Learn more about their key similarities, ...

Pyzchiva is supplied as a 45mg/0.5mL and a 90mg/mL single-dose prefilled syringe for subcutaneous (SC) injection, and a 130mg/26mL single-dose vial for intravenous (IV) infusion. According to ...

JERSEY CITY, N.J., March 12, 2025 /PRNewswire/ -- Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA ... in a single-dose, prefilled syringe.

The suit seeks a preliminary injunction to bar U.S. sales of the private-label version of Samsung Bioepis' Stelara biosimilar, called Pyzchiva. Sign up here. Samsung and J&J signed a settlement ...

allowing for flexible dosing options based on patient needs. Celltrion is launching Steqeyma at an 85 percent lower wholesale acquisition cost, or WAC, than Stelara. The company said this pricing ...

(Reuters) - Johnson & Johnson (NYSE:JNJ) sued Samsung (KS:005930) Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to Stelara, J&J's blockbuster psoriasis ...

Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's blockbuster drug Stelara, also known as ustekinumab. The drug is used to ...

As a major component of the Connect 360 Autoimmune Program expansion, SmithRx will help employer clients and their employees adopt biosimilars, representing over 95% savings compared to Stelara ...

Navitus will remove Stelara from formulary on July 1, 2025. Stelara, the brand name of the drug ustekinumab, is a popular treatment for plaque psoriasis, psoriatic arthritis, ulcerative colitis ...

Biocon Biologics has announced that Yesintek (ustekinumab-kfce) is now available to patients in the United States, and is one of the first Stelara (ustekinumab ... covering the same indications and ...